ArticleBMC microbiology2026
Limosilactobacillus fermentum SPC L75-1: a novel sourdough starter enhancing bread quality and exhibiting postbiotic immunomodulatory activity.
Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sourdough is a mixture of water and flour fermented by yeast and lactic acid bacteria, enhancing its nutritional value, digestibility, shelf-life, and flavor. This study explored the potential of Limosilactobacillus fermentum SPC L75-1 as a novel sourdough starter by investigating its effects on baking characteristics and postbiotic properties. The SPC L75-1 strain utilized maltose, and its fermentation resulted in a volatile profile similar to that of the control bread. The application of SPC L75-1 to bread improved gas production by 18.5% and resulted in lower hardness compared to the control. Regarding its postbiotic potential, SPC L75-1 exhibited potent antioxidant and anti-inflammatory activities, reducing nitric oxide (NO) production by 42.1% and suppressing pro-inflammatory cytokines in an in vitro LPS-induced RAW 264.7 model. Furthermore, safety assessments, including hemolytic activity and antibiotic susceptibility tests, confirmed the strain’s suitability for food applications. Genome analysis further identified genes associated with these functional and safety traits. This study demonstrates that L. fermentum SPC L75-1 is a promising starter for sourdough fermentation, enhancing both bread quality and health benefits.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.